Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

NCT06838910 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Thymic Carcinoma
Thymoma

Interventions

DRUG: Experimental: tislelizumab+anlotinib

Sponsor

The First Affiliated Hospital with Nanjing Medical University